Published in Cancer Weekly, February 22nd, 2000
The authors found that the anti-CD22 antibody labeled with iodine-131 had an objective response rate of 33% (complete and partial responses) in a Phase I study of non-Hodgkin's lymphoma patients. Furthermore, 71% of the responders had a complete remission.
Dr. David M. Goldenberg, Immunomedics, stated: "This was a study, concluded in 1997, involving 21 patients given repeated injections of our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.